Human peripheral blood Vα24+ Vβ11+ NKT cells expand following administration of α‐galactosylceramide‐pulsed dendritic cells
Copyright policy )Human peripheral blood Vα24+ Vβ11+ NKT cells expand following administration of α‐galactosylceramide‐pulsed dendritic cells
Background and Objectives We have undertaken the first clinical trial involving the administration of α‐GalactosylCeramine (α‐GalCer)‐pulsed dendritic cells (DCs) to human subjects, to determine safety, optimal dose, optimal administration route and immunological effects.Materials and Methods Subjects (n = 4) with metastatic malignancy received two infusions of α‐GalCer‐pulsed DCs intravenously, and two infusions intradermally. The percentages of Vα24 Vβ11 NKT cells in peripheral blood (PB) were determined by three‐colour flow cytometry and the PB NKT cell numbers were calculated using the total number of PB lymphocytes/ml determined by automated full‐blood counts.Results No serious treatment related adverse events were observed during the study period. Administration of α‐GalCer‐pulsed DCs in vivo can significantly (P < 0·03) increase PB Vα24+ Vβ11+ NKT cell numbers above pretreatment baseline levels after the transient fall in the NKT numbers within 48 h.Conclusions Administration of α‐GalCer‐pulsed DCs is well tolerated, modulates PB Vα24+ Vβ11+ NKT cells and may have a role in the therapy of malignancies sensitive to activities of Vα24+ Vβ11+ NKT cells, or for autoimmune diseases.
- University of Tokyo Japan
- University of Queensland Australia
- Juntendo University Japan
- Gulf Coast Regional Blood Center United States
- QIMR Berghofer Medical Research Institute Australia
Tumour Immunity, T-Lymphocytes, Activation, 610, Galactosylceramides, Immunotherapy, Adoptive, Autoimmune Diseases, Metastasis, C1, Neoplasms, Humans, Glycosylceramides, Lymphocyte Count, Blood Cells, Nkt Cells, Alpha-galactosylceramide, Hematology, 320206 Tumor Immunology, Dendritic Cells, 730108 Cancer and related disorders, Flow Cytometry, Killer Cells, Natural, Treatment Outcome, Cell Division, Human
Tumour Immunity, T-Lymphocytes, Activation, 610, Galactosylceramides, Immunotherapy, Adoptive, Autoimmune Diseases, Metastasis, C1, Neoplasms, Humans, Glycosylceramides, Lymphocyte Count, Blood Cells, Nkt Cells, Alpha-galactosylceramide, Hematology, 320206 Tumor Immunology, Dendritic Cells, 730108 Cancer and related disorders, Flow Cytometry, Killer Cells, Natural, Treatment Outcome, Cell Division, Human
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).45 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!